Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b placebo-controlled study of macitentan in HFpEF with pulmonary vascular disease
MOH_2017-09-03_000446Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) comparing Opsumit with Placebo (2 arms). Primary endpoint: NT-proBNP at week 24 as percent of baseline. Started Jun 2017; status: completed.
02
Drugs
macitentan
03
Conditions
heart failure with preserved ejection fraction (HFpEF)pulmonary vascular disease (PVD)
Beyond the preview
Go deeper on MOH_2017-09-03_000446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-03_000446.